Navigation Links
Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors

SEATTLE--(BUSINESS WIRE)--Jun 1, 2007 - Introgen Therapeutics, Inc. (NASDAQ:INGN) reported promising Phase 1/2 clinical data with INGN 241, the Company's novel investigational mda-7/IL-24 tumor suppressor agent, in patients with advanced solid tumors.

The data (Abstract #380), which were presented today at the annual meeting of the American Society of Gene Therapy, showed that in this 22-patient trial, INGN 241 induced killing in all treated tumors, including in those patients who failed prior therapy with other anti-cancer agents. INGN 241 was well tolerated, and a maximum tolerated dose was not reached. Tumor growth control was observed in 44 percent of treated tumors. Two of five patients treated at the highest dose showed objective responses (greater than 50 percent reduction in tumor size). Increases in the number of immune cells known to mediate anti-tumor effects were also observed in all patients, consistent with the immune-stimulating activity of INGN 241.

Although INGN 241 was administered directly to tumors, evidence of distant biologic activity was observed, suggesting that this therapy may have utility in treating primary tumors as well as metastatic disease. INGN 241 treatment in combination with radiotherapy is being evaluated in an ongoing Phase 3 trial in solid tumors, including patients with head and neck cancer.

"These data are particularly encouraging because they demonstrate INGN 241 has clinical activity even in patients who have failed previous therapies," said Sunil Chada, Ph.D., associate vice president, Clinical Research and Development at Introgen.

INGN 241 Shown to Restore Platinum Sensitivity in Preclinical Studies

Data from preclinical studies of INGN 241 also were presented (Abstract #197) that evaluated the ability of INGN 241 to restore cisplatin sensitivity to ovarian cancer cells that are cisplatin-resistant. The results showed that INGN 241 effecti
'"/>




Page: 1 2 3

Related medicine technology :

1. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
2. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
3. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
4. Preclinical Studies Identify Novel Approach for Enhancing the Anticancer Activity of Introgens INGN 241
5. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
6. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
7. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
10. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
11. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
Post Your Comments:
(Date:8/28/2014)... DENVER , Aug. 28, 2014 ... a two-year investment into this game-changing method for ... Today, clinical trials target specific cancers, ... be contributing factors for the cancer, in the ... is that this information may not be well ...
(Date:8/28/2014)... 28, 2014  In anticipation of the upcoming MEDevice ... available for the first time. Industry Overview: Medtech & ... offers a snapshot of San Diego,s ... from the latest employment statistics to current venture capital investment ... Diego such a vital part of the global ...
(Date:8/28/2014)... MINNEAPOLIS , Aug. 28, 2014 Nonin ... a leader in noninvasive medical monitoring, today announced that ... Nonin Model 3231 OEM/eHealth finger pulse oximeter for use ... finger pulse oximeter plugs into a telemedicine hub or ... and pulse rate in pediatric to adult patients. The ...
Breaking Medicine Technology:Enrollment in Pharmatech's Revolutionary AccessPPM Program Launches 2New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... Weiss, Director of Maryland Laser, Skin and Vein,Institute, ... BALTIMORE, Oct. 2 Robert Weiss, M.D., board ... U.S. to offer his,patients DOT Therapy (Dermal Optical ... Dr. Weiss is an,internationally renowned dermatologist, who is ...
... Biotechnologies AB and Dyax,Corp. (NASDAQ: DYAX ) ... a,collaboration to discover and to develop therapeutic ... inflammatory diseases., The collaboration follows the ... Professors Frostegard and de Faire of the ...
Cached Medicine Technology:DOT Therapy: Newest Breakthrough Technology in Laser Skin Resurfacing 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 2Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 3Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation 4
(Date:8/28/2014)... 2014) Solid-head power toothbrushes retain less bacteria ... The University of Texas Health Science Center at ... the study are published in the August issue ... and professor at the UTHealth School of Dentistry, ... counts were lower in the solid-head toothbrush group ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 ISI ... management solutions, will be sponsoring the 2014 Presidio ... annual event allows Presidio leadership to engage with ... year. Specifically, they will be rolling out objectives ... , While at the event, ISI will be ...
(Date:8/28/2014)... A candidate Ebola vaccine could be given to healthy ... early as September, as part of an series of ... disease that has killed more than 1,400 people in ... of this candidate vaccine, being co-developed by the US ... be accelerated with funding from an international consortium in ...
(Date:8/28/2014)... prevent Ebola virus disease will begin next week by ... part of the National Institutes of Health. , The ... vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will ... an immune system response in healthy adults. Testing will ... Maryland. , The study is the first of several ...
(Date:8/28/2014)... People aged 70 and over who identify themselves as ... where they perceive they have lower value than younger ... University of Kent, titled ,Being old and ill, across ... subjective health, used data from the European Social Survey. ... asked to self-rate their health., The researchers found that ...
Breaking Medicine News(10 mins):Health News:UTHealth researchers find up to 3,000 times the bacterial growth on hollow-head toothbrushes 2Health News:ISI Telemanagement Solutions, Inc. to Sponsor 2014 Presidio Exchange 2Health News:Ebola vaccine trials fast-tracked by international consortium 2Health News:Ebola vaccine trials fast-tracked by international consortium 3Health News:Ebola vaccine trials fast-tracked by international consortium 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 2Health News:NIH to Launch human safety study of Ebola vaccine candidate 3Health News:NIH to Launch human safety study of Ebola vaccine candidate 4Health News:NIH to Launch human safety study of Ebola vaccine candidate 5
... become one of the major public health problems in developed ... a researcher at the University of Zaragoza (UNIZAR), tells SINC. ... than two hours of television per day. At weekends, this ... July issue of the journal Preventive Medicine , show ...
... HealthDay Reporter , THURSDAY, Sept. 16 (HealthDay News) -- ... -- also known as cryotherapy -- works better than applying ... No one treatment cured more than half of cases, ... needed, experts say. The new finding is a bit ...
... Round Rock, Texas is recruiting patients for a Phase ... recurrence in previously treated patients. The trial will ... Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung ... Cell LunG Cancer Immunotherapy) study is expected to be ...
... Jenifer Goodwin HealthDay Reporter , THURSDAY, Sept. 16 ... risk of colorectal cancer, new research finds. Prior research ... colon cancer. But this study is among the first to ... side effects such as gastrointestinal bleeding -- may also be ...
... patients develop post-traumatic stress syndrome (PTSD) after the trauma ... to be exacerbated by delusional or fragmentary memories of ... writing in BioMed Central,s open access journal Critical ... relatives make a diary for patients, featuring information about ...
... significant and lasting relief for patients with myelofibrosis, a ... University of Texas MD Anderson Cancer Center report in ... . Myelofibrosis is caused by the accumulation of ... scarring the bone marrow and limiting its ability to ...
Cached Medicine News:Health News:Teenagers are more sedentary on weekends 2Health News:For Common Warts, Freezing Therapy Works Best: Study 2Health News:For Common Warts, Freezing Therapy Works Best: Study 3Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 2Health News:Low-Dose Aspirin May Reduce Colon Cancer Risk 3Health News:Intensive care diaries protect patients from PTSD 2Health News:JAK inhibitor provides rapid, durable relief for myelofibrosis patients 2Health News:JAK inhibitor provides rapid, durable relief for myelofibrosis patients 3
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Straight heavy shafts with delicate 7 mm tying platform. Sharp pointed tips for removing fine sutures. Wide serrated handle with polished finish. Overall length 4.1 inches....
Angled 45 degree shafts with 10.5 mm tying and 1 mm of tip crisscross serrated. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.2 inches....
Curved, 7 mm tying platform. Castroviejo handle. Manufactured in titanium. Overall length 4.2 inches....
Medicine Products: